Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genome Analysis Toolkit Developed for Next-Generation Sequencing

By LabMedica International staff writers
Posted on 31 Oct 2012
A new genome analysis toolkit (GATK) provides an open-source computational engine enabling the development of analysis tools for next-generation sequencing. More...
Upon this engine, scientists have constructed a wide series of analysis tools to process data from any next-generation sequencing platform, and to identify changes in the sequences that may be associated with disease.

The Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University (Boston, MA, USA) has chosen Appistry, Inc. (St. Louis, Mo, USA) to distribute the toolkit to users at for-profit companies one of the most widely used software for data processing and variant calling of next-generation sequencing data, and to provide those users with commercial-grade customer support.

First developed and introduced by the Broad Institute in 2009, the GATK user base has grown to include thousands of biomedical researchers, bioinformatics professionals, and clinicians from a wide-range of both nonprofit as well as for-profit organizations. The GATK has been used on initiatives ranging from the 1000 Genomes Project to the National Institutes of Health’s (NIH; Bethesda, MD, USA) Cancer Genome Atlas, and by many sequencing centers and leading researchers to conduct population studies and explore the genetic origins of disease.

“Genetic research is changing the face of modern healthcare, and tools like the GATK have been essential in making the reams of data coming off of sequencers actionable,” said Appistry chief executive officer Kevin Haar. “We are honored to have been chosen to help the Broad Institute bring GATK 2.0, with customer support, to for-profit users and ensure that it remains an important source of insight in deciphering the genetic code and better managing and treating human disease.”

The GATK framework supports a wide variety of tools, with a primary focus on variant discovery and genotyping as well as strong emphasis on data quality assurance. Its architecture, powerful processing engine, and high-performance, scalable computing capabilities enable it to work on projects of any size. GATK 2.0 brings considerable enhancement over earlier releases of the toolkit, including newer and more sophisticated tools for error modeling, data compression, and variant calling.

GATK 2.0 will continue to be freely available to non-profit users under an academic, nonprofit research license agreement. Appistry will make the toolkit available to users at for-profit companies under a separate license agreement with a subscription fee that will cover commercial-grade support for installation, configuration, and documentation as well as long-term support for each commercial release. GATK 1.0, now called GATK-lite, will remain free for all users.

“We have been thrilled that the GATK has proven useful to a diverse group of users. However, as an academic institution, we don’t have the resources to offer the level of support that many for-profit users of the GATK want and need,” said David Altshuler, deputy director of the Broad Institute. “By partnering with Appistry, we are able to continue to provide the toolkit for free to nonprofit users, and to continue to extend its capabilities, while also ensuring the kind of support that users at for-profit companies have been looking for.”

Appistry combines high performance computing and analytics to provide the throughput and scale required for diverse applications--from discovering new medical therapies to delivering overnight packages, decoding military satellite images, or gaining insights from financial transactions.

The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute’s goal is to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, techniques, and data openly to the entire scientific community.

Related Links:
Broad Institute of the Massachusetts Institute of Technology and Harvard University
Appistry




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.